BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 29
• 30

• 

  Drug Development

  Novartis Provides Additional Phase III Data for MS Drug Siponimod: Prepares to Seek FDA Approval

  Novartis released new information that showed siponimod consistently reduced the risk of confirmed disability progression in secondary progressive multiple sclerosis (SPMS) patients.

  April 20, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Bluebird Bio One Step Closer to its First Approved Drug

  Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).

  April 20, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  CAR-T Trailblazer Carl June Who Collaborated on Novartis’ Kymriah Makes Time’s 100 Influential List

  A pioneer in CAR-T therapies has been named one of Time Magazine’s 100 most influential people in the world for 2018.

  April 20, 2018

   · 

  2 min read

   · 

  Alex Keown